Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Respiratory failure? 1,116 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,116 reports of Respiratory failure have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 1.4% of all adverse event reports for DOXORUBICIN.

1,116
Reports of Respiratory failure with DOXORUBICIN
1.4%
of all DOXORUBICIN reports
620
Deaths
687
Hospitalizations

How Dangerous Is Respiratory failure From DOXORUBICIN?

Of the 1,116 reports, 620 (55.6%) resulted in death, 687 (61.6%) required hospitalization, and 308 (27.6%) were considered life-threatening.

Is Respiratory failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 1,116 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Respiratory failure?

PREDNISONE (2,299) CYCLOPHOSPHAMIDE (2,096) RITUXIMAB (1,838) TACROLIMUS (1,758) METHOTREXATE (1,685) DEXAMETHASONE (1,603) MYCOPHENOLATE MOFETIL (1,469) METHYLPREDNISOLONE (1,442) PREDNISOLONE (1,346) VINCRISTINE (1,120)

Which DOXORUBICIN Alternatives Have Lower Respiratory failure Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Respiratory failure Reports All Drugs Causing Respiratory failure DOXORUBICIN Demographics